drugset / Trial / NCT01456624

Phase 1 Study of Daewon-ES(B) & Megace in Healthy Male Volunteers Under Fasting and Fed Condition

NCT01456624

Phase 1 Completed 56 enrolled Asan Medical Center
RandomizedCrossoverOpen-labelSupportive care

Summary

The purpose of this study is to evaluate pharmacokinetics of Daewon DW-ES(B) 625mg/5ml and Megace 800mg/20ml in healthy male volunteers under fasting and fed condition.

Timeline

Start
2011-09
Primary completion
2012-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject DW-ES(B) Unknown 625 mg
Comparator Megestrol Acetate Other / unclassified 800 mg

Indications

No indication recorded.